Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.

@article{McCaffery1996ImmunizationOM,
  title={Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.},
  author={Michael J McCaffery and Tzy Jyun Yao and Linda D Williams and Philip O. Livingston and Alan N. Houghton and Paul B Chapman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1996},
  volume={2 4},
  pages={679-86}
}
Previous attempts to immunize melanoma patients against GD3 ganglioside have been unsuccessful because of the poor immunogenicity of GD3. BEC2, an anti-idiotypic monoclonal antibody that mimics GD3, can induce anti-GD3 IgG in rabbits. Since clinical trials with BEC2 in melanoma patients demonstrated that BEC2 alone is not highly immunogenic, we have carried out sequential clinical trials exploring the use of two immunological adjuvants, BCG and QS21, administered with BEC2. Melanoma patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Immunotherapy in lung cancer.

View 4 Excerpts
Highly Influenced

Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

Clinical cancer research : an official journal of the American Association for Cancer Research • 1998
View 7 Excerpts
Highly Influenced

Immunotherapy in lung cancer.

Translational lung cancer research • 2014
View 1 Excerpt

[Advances of immunotherapy in small cell lung cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer • 2014

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Immunization with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: superiority of the intravenous route

P. B. Chapman, M. McCaffery, K. Zuklys, N. Giorgio, A. N. Houghton
Proc. Am. Assoc. Cancer Res., • 1995
View 1 Excerpt

Impact of immunological adjuvants and administration route on HAMA response after immunization with murine monoclonal antibody MELIMMUNE-l in melanoma patients

Livingston, S. Adluri, +3 authors J. A. Memt
Vaccine Res., • 1995
View 1 Excerpt

Immunization of melanoma patients with antiidiotypic monoclonal antibody BEC2 which mimics GD3 ganglioside: pilot trials using no immunological adjuvant

P. B. Chapman, Livingston, M. E. Morrison, L. Williams, A. N. Houghton
Vaccine Res., • 1994
View 2 Excerpts

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1994
View 1 Excerpt

The prognosis of patients with stage III melanoma. Prospective long-term study of 286 patients of the Fachklinik Horneide

H. Drepper, B. Bieb, +6 authors H. Wiebelt
Cancer (Phila.), • 1993
View 1 Excerpt

Similar Papers

Loading similar papers…